Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Neuroscience-based biotechnology company Elan and Germany-based Boehringer Ingelheim have entered into a global technical development and manufacturing agreement for antibody-based therapeutics.
Subscribe to our email newsletter
Boehringer Ingelheim will carry out the technical development, clinical manufacturing and all related regulatory filing support services for antibodies discovered by Elan.
Elan will guide the discovery science, preclinical activities, clinical development and commercialization of such antibodies.
Elan senior vice president and head of Biologic Strategy Johannes Roebers said the agreement enables Elan to focus resources on discovery and the clinical progression of their science while leveraging Boehringer Ingelheim’s process development and production capabilities.
Boehringer Ingelheim Biopharmaceuticals Division corporate senior vice president Simon Sturge said the combination of Elan’s successful track record in the discovery and clinical development of antibody-based therapeutics with their proven expertise in technical development and manufacturing and in particular BI HEX® platform, will be an optimal fit.